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Summary
 
Autoreactive anti–MHC class II T cells are found in Brown Norway (BN) and Lewis (LEW)
rats that receive either HgCl
 
2
 
 or gold salts. These T cells have a T helper cell 2 (Th2) pheno-
type in the former strain and are responsible for Th2-mediated autoimmunity. In contrast,
T cells that expand in LEW rats produce IL-2 and prevent experimental autoimmune enceph-
alomyelitis, a cell-mediated autoimmune disease. The aim of this work was to investigate, using
T cell lines derived from HgCl
 
2
 
-injected LEW rats (LEWHg), the effect of these autoreactive
T cells on the development of Th2-mediated autoimmunity. The five LEWHg T cell lines ob-
tained protect against Th2-mediated autoimmunity induced by HgCl
 
2
 
 in (LEW 
 
3
 
 BN)F1 hy-
brids. The lines produce, in addition to IL-2, IFN-
 
g
 
 and TGF-
 
b
 
, and the protective effect is
TGF-
 
b
 
 dependent since protection is abrogated by anti-TGF-
 
b
 
 treatment. These results iden-
tify regulatory, TGF-
 
b
 
–producing, autoreactive T cells that are distinct from classical Th1 or
Th2 and inhibit both Th1- and Th2-mediated autoimmune diseases.
 
M
 
ercuric chloride or gold salts induce in Brown Nor-
way (BN)
 
1
 
, in (Lewis [LEW] 
 
3
 
 BN)F1 hybrids, and
in susceptible mice, a transient Th2-dependent B cell poly-
clonal activation (1–4) responsible for an increase in serum
IgE concentration and for the production of various au-
toantibodies including anti-DNA and antilaminin antibod-
ies (for review see reference 1). These latter antibodies are
associated with the occurrence of an autoimmune glomer-
ulonephritis as observed in some patients treated with gold
salts (5). T cells that recognize either self–MHC class II
molecules or an ubiquitous self-peptide presented by MHC
class II molecules play an important role in the induction of
B cell polyclonal activation in this model (6, 7). In contrast,
HgCl
 
2
 
 provokes in LEW rats, a nonantigen-specific suppres-
sion and protects from autoimmune diseases such as experi-
mental autoimmune encephalomyelitis (EAE) to which this
strain is otherwise highly susceptible. Autoreactive anti-self–
MHC class II T cells have also been detected in HgCl
 
2
 
-
injected LEW rats (8). Autoreactive T cell lines have been
derived from gold-injected BN rats and HgCl
 
2
 
-injected
LEW rats (LEWHg T cell lines) by repeated stimulations
with syngeneic APCs. In both strains, these anti–MHC class
II T cell lines are RT1.B- (mouse IA equivalent), but not
RT1.D- (mouse IE equivalent) restricted (7, 8). Whereas T
cell lines derived from BN rats produce IL-4 and are able to
passively transfer autoimmunity into CD8-depleted naive
BN rats (7), the LEWHgA T cell line, derived from
HgCl
 
2
 
-injected LEW rats, produces IL-2 and IFN-
 
g
 
 and
protects LEW rats against EAE, a Th1-mediated autoim-
mune disease, by inducing regulatory CD8
 
1
 
 T cells (8).
The aim of this study was to assess the effect of adoptive
transfer of LEWHg T cell lines on the course of Th2-
mediated autoimmunity induced by HgCl
 
2
 
 in (LEW 
 
3
 
BN)F1 hybrids. We show that (
 
a
 
) the lines produce TGF-
 
b
 
in addition to IL-2 and IFN-
 
g
 
, (
 
b
 
) adoptive transfer of the
lines prevents HgCl
 
2
 
-induced autoimmunity, and (
 
c
 
) this
protection is abrogated after anti-TGF-
 
b
 
 mAb administra-
tion.
 
Materials and Methods
 
Rats
 
BN and LEW rats were obtained from Charles River (Rouen,
France) and maintained in our facilities. F1 hybrids were obtained
by crossing BN male and LEW female rats in our animal house.
8–12-wk-old males or females were used in the experiments.
 
1
 
Abbreviations used in this paper:
 
 AU, arbitrary units; BN, Brown Norway;
EAE, experimental autoimmune encephalomyelitis; LEW, Lewis; LEWHg,
HgCl
 
2
 
-injected LEW rats.
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Culture Medium
 
RPMI 1640 (Biochrom KG, Berlin, Germany) was supple-
mented with streptomycin (100 
 
m
 
g/ml) and penicillin (100 U/ml),
nonessential amino acids (0.1 mM), L-glutamine (2 mM; GIBCO,
Paisley, U.K.), sodium pyruvate (1 mM; Biochrom KG), and 2-ME
(5 
 
3
 
 10
 
2
 
5
 
 M); Sigma Chemical Co., St. Louis, MO).
 
mAbs and FACS
 
Ò
 
 Analysis
 
R73, W3/25, OX8, OX81, and B10.H2 mAbs are mouse
IgG1 mAbs that recognize rat TCR-
 
a
 
/
 
b
 
 chains (9), CD4 (10),
CD8 (11), rat IL-4 (12), and thyroglobulin, respectively. The
IgG1 1D11.16 and the IgG2a 2G.7 anti-TGF-
 
b
 
 mAbs were pro-
vided by Dr. W. Waegell (Celtrix Pharmaceuticals, Santa Clara,
CA; 13) and by Dr. C.M. Melief (University of Leiden, Leiden,
Netherlands; 14), respectively. The IgG1 DB.1 and DB.12 anti-
IFN-
 
g
 
 mAbs were provided by Dr. P.H. Van der Meide (15) and
B10.H2 mAb by Dr. D. Glotz (Paris, France). The W3/25 and
OX8 hybridomas were obtained from the Public Health Labora-
tory Service (Oxford, U.K.); Dr. T. Hunig (Würzburg, Ger-
many), and Dr. D. Mason (Medical Research Council, Oxford,
U.K.) provided the R73 and OX81 hybridomas, respectively. As-
cites and purified antibodies were prepared as described (16).
The phenotype of cells was determined by double staining;
cells were incubated with FITC-labeled W3/25 and biotinylated-
OX8 mAb, and then streptavidin-phycoerythrin (Sigma Chemi-
cal Co.) was added. The cells were analyzed with a Coulter Epics
XL (Coultronics, Margency, France); a minimum of 5,000 cells
were counted.
 
T Cell Lines
 
The five LEWHg T cell lines (LEWHg A, B, C, D, and E)
used in this study have been previously described (8). They were
derived from lymph node cells of five distinct LEW rats injected
with HgCl
 
2
 
 for 7 d; they are CD4
 
1
 
CD8
 
2
 
TCR-
 
a
 
/
 
b
 
1
 
, proliferate
in the presence of syngeneic APCs, and are MHC class II
(RT1.B)–restricted. The LEWOVA T cell line was also a CD4
 
1
 
CD8
 
2
 
 TCR-
 
a
 
/
 
b
 
1
 
 T cell line derived from the draining lymph
nodes of a LEW rat immunized 10 d before with 100 
 
m
 
g OVA in
CFA. Except when otherwise mentioned, T cell lines were stim-
ulated repeatedly every 2 wk as follows: 2 
 
3
 
 10
 
5
 
 cells/well were
cultured in 24-well flat-bottomed plates (Nunc, Kamstrup, Den-
mark), in a 6% CO
 
2
 
 incubator in the presence of normal irradi-
ated (3,000 rads) syngeneic thymocytes (5–10 
 
3
 
 10
 
6
 
/well), in a
volume of 1 ml/well culture medium supplemented with 10% heat-
inactivated FCS and 10% Con A supernatant (8). The LEWOVA
T cell line was stimulated with 50 
 
m
 
g/ml OVA (Sigma Chemical
Co.).
 
Cytokine Assays
 
T cell lines were stimulated with irradiated thymocytes as de-
scribed above, in the absence of Con A supernatant; 24-, 48-, 72-,
96-, and 120-h culture supernatants were collected and stored at
 
2
 
20
 
8
 
C. IL-2 production was assessed using proliferation of the
IL-2–dependent CTLL-2 cell line (7). IFN-
 
g
 
 production was
determined by two-site sandwich ELISA (7). Values were ex-
pressed as U/ml IFN-
 
g
 
 referring to a standard curve constructed
using serial dilutions of recombinant purified rat IFN-
 
g
 
 (a gift
from Dr. P. van der Meide, Vrije Universiteit, Amsterdam, Neth-
erlands). IL-4 detection was based upon the ability of this cyto-
kine to upregulate MHC class II molecule expression on B cells
 
(12). The assay was performed, in the presence or in the absence
of the OX81 anti–rat IL-4 mAb (50 
 
m
 
g/ml), by fluorocytometry.
Recombinant rat IL-4, (provided by Dr. D. Mason, Medical Re-
search Council, CIU, Oxford, U.K.) was used as a positive con-
trol.
TGF-
 
b
 
 was measured by ELISA (R&D Sys., Inc., Abingdon,
U.K.) according to the manufacturer’s instructions. To demon-
strate that TGF-
 
b
 
 was produced by T cells and not by APCs, the
LEWHgA T cell line was also stimulated as follows: 96 flat-bot-
tomed well plates were precoated with rabbit anti–mouse Ig anti-
bodies (DAKOPATTS, Copenhagen, Denmark) overnight; the
LEWHgA T cell line was then added (5 
 
3
 
 10
 
4
 
/well), together
with mouse anti–rat TCR-
 
a
 
/
 
b
 
 mAb (50 
 
m
 
g/ml) as described
elsewhere (9). Supernatant was collected after 24, 48, and 96 h.
Cells were also cultured for 72 h to assess the proliferative re-
sponse. The anti–rat TCR-
 
a
 
/
 
b
 
 mAb was replaced in control cul-
tures by the B10.H2 mAb.
 
Experimental Design
 
HgCl
 
2
 
 Injections and Follow Up of Mercury Disease.
 
Rats were in-
jected with HgCl
 
2
 
 (100 
 
m
 
g/100 g body wt, subcutaneously, 3
times/wk) during 4 to 6 wk (6). All the rats were bled once a
week for determination of serum IgE concentration, antilaminin,
and occasionally, anti-DNA antibody titers as previously de-
scribed (17, 18). Kidneys were processed at the time of killing for
immunofluorescence studies, using FITC-conjugated sheep anti–
rat IgG antiserum as previously described (7). The intensity of
fluorescence was scored on a scale from 0 to 4 in blind study by
two independent examiners.
 
Adoptive Transfer of T Cell Lines.
 
T cell lines (LEWHgA, LEWHgB,
LEWHgC, LEWHgD, and LEWHgE) were stimulated for 3 d
with syngeneic irradiated thymocytes only or LEWOVA with
syngeneic irradiated thymocytes plus ovalbumin. T cell lines (10
 
7
 
cells) were then intraperitoneally injected into naive F1 rats 2 wk
before the first HgCl
 
2
 
 injection.
 
Thymectomy, Anti-CD8, and Anti-TGF-
 
b
 
 Treatment.
 
Rats were
thymectomized at 8 wk of age (19), allowed to recover for 3
wk, and then injected with the LEWHgA T cell line; 15 d later,
rats were injected with HgCl
 
2
 
. In addition, some rats received the
anti-CD8 (OX8) mAb or the control isotype-matched B10.H2
mAb (500 
 
m
 
g intraperitoneally, once a week for 1 mo) from the
first HgCl
 
2
 
 injection (8). The effect of TGF-
 
b
 
 neutralization was
assessed using the anti-TGF-
 
b
 
 mAbs 1D11.16 or 2G.7 (2 mg in-
traperitoneally on days 
 
2
 
2, 0, 3, 6, and 9 with respect to the first
HgCl
 
2
 
 injection).
 
Statistical Analysis
 
Serum IgE concentration, antilaminin, and anti-DNA anti-
body titers were compared between the different groups by using
nonparametrical tests. The number of rats per group with kidney-
bound IgG was compared by chi-square analysis.
 
Results
 
Description of T Cell Lines.
 
As previously described (8),
the five LEWHg T cell lines used in this study are CD4
 
1
 
CD8
 
2
 
TCR-
 
a
 
/
 
b
 
1
 
 and proliferate in the presence of nor-
mal syngeneic MHC class II
 
1
 
 APCs. They all produced IL-2
and IFN-
 
g
 
 (Table 1) with a peak at 24 h for IL-2 and 48
or 72 h for IFN-
 
g
 
. The LEWHg, but not the LEWOVA, 
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T cell lines produced TGF-
 
b
 
 (Table 1) with a peak at 96 or
120 h of stimulation. None of these cytokines were de-
tected in supernatants from irradiated APCs only, or in su-
pernatants of resting T cell lines (Table 1). To eliminate a
role for APCs in producing TGF-
 
b
 
, the LEWHgA T cell
line was stimulated by plate-bound anti-TCR mAb in the
absence of APCs. In such conditions, the LEWHgA T cell
line proliferated (index 3 
 
6
 
 0.5) and produced TGF-
 
b
 
(1.72 
 
6 0.05 ng/ml). No proliferation and no TGF-b se-
cretion were observed when the anti-TCR mAb was re-
placed by the control B10.H2 mAb.
The supernatant from the stimulated LEWHgB T cell line
increased MHC class II expression on B cells (mean fluo-
rescence intensity of 51 versus 10 for B cells cultured
alone), and this increase was abolished by addition of the
anti-IL-4 OX81 mAb (mean fluorescence intensity of 14)
suggesting that this line produced IL-4. None of the other
LEWHg or LEWOVA T cell lines produced detectable
amounts of IL-4 in this assay (not shown).
Anti–MHC Class II LEWHg T Cell Lines Prevent HgCl2-
induced Autoimmunity in F1 Rats Transfer of the LEWHgA
T cell line at the time of the first HgCl2 injection attenu-
ated the autoimmune manifestations, but did not com-
pletely prevent the polyclonal activation of B cells nor renal
IgG deposition (data not shown). By contrast, HgCl2-induced
immunopathological manifestations were abrogated or con-
siderably reduced in rats that received the LEWHg T cell
lines 15 d before the first HgCl2 injection. In these rats, an-
tilaminin antibody titer was much lower as compared to
that of HgCl2-injected rats (P ,0.005) and did not differ
from that observed in normal rats (Fig. 1, A and B). Similar
results were obtained concerning anti-DNA antibodies (not
shown). Serum IgE concentration dramatically decreased
when compared to HgCl2-injected rats (P ,0.01), but re-
mained higher than in normal rats (Fig. 1, C and D). The
number of rats with glomerular IgG deposits was reduced
in those who received the LEWHg T cell lines (from 66 to
19% depending upon the line, versus 100% in rats that re-
ceived HgCl2 only; P ,0.01); when considering rats that
still exhibited IgG glomerular deposits, the intensity of im-
munofluorescence was greatly diminished when compared
to rats injected with HgCl2 only (Fig. 2). Transfer of the
LEWOVA T cell line had no effect on HgCl2-induced au-
toimmunity; these rats behaved as rats injected with HgCl2
only with respect to serum IgE concentration, antilaminin
antibody titer (Fig. 1, A and C), and glomerular IgG depos-
its (Fig. 2).
CD81 Cells and Recent Thymic Emigrants Are Not Involved
in the Protection. Since we had previously observed that
the LEWHgA T cell line protects from EAE in a CD8-depen-
dent manner (8), the potential role of CD81 cells was ad-
dressed in the present model. To achieve CD81 cell de-
pletion, rats were thymectomized and injected with the
anti-CD8 mAb. These rats displayed ,1.5% CD81 cells in
spleen and lymph nodes at the time of killing, compared to
15 6 3% in control rats. In these rats, HgCl2 injections in-
duced similar, or even more severe, manifestations than in
control rats injected with HgCl2 (Fig. 3, A and B). Transfer
of the LEWHgA T cell line inhibited HgCl2-induced anti-
laminin antibody production (Fig. 3 A), increase in serum
Table 1. Cytokines Produced by the LEWHg and LEWOVA
T Cell Lines
Line (No. of exp.) IL-2* IFN-g TGF-b
cpm 3 1023 U/ml ng/ml
LEWHgA (8) 12 6 3.5 15 6 9 2.3 6 0.9
LEWHgB (2) 8, 6 10, 13 1.7, 0.9
LEWHgC (2) 14, 7 21, 9 0.45, 0.39
LEWHgD (2) 8, 12 2, 4.5 0.15, 0.3
LEWHgE (2) 9.6, 15 13, 15 0.6, 0.5
LEW OVA (5) 10.5 6 1.5 12 6 3 ,0.1
Unstimulated lines 0.5 6 0.1 0 ,0.1
Results are expressed as mean 6 SD when five or eight experiments
were performed; otherwise individual values were given.
*The background value of CTLL-2 cells was 700 6 150 cpm. 
Figure 1. Ability of the LEWHg T cell lines to protect F1 rats against
HgCl2-induced immune disorders. Antilaminin antibody titer (A and B)
and serum IgE concentration (C and D) in HgCl2-injected rats (h, n 5
25); normal rats ( , n 5 5); rats injected with HgCl2 and, 2 wk before,
with the LEWOVA (r, n 5 5), LEWHgA (j, n 5 21), LEWHgB (s, n 5
3), LEWHgC (d, n 5 3), LEWHgD ( , n 5 3) or LEWHgE (e, n 5
6) T cell line. AU, arbitrary units.1772 Self–MHC Class II–reactive T Cells Abolish Th2-mediated Autoimmunity
IgE concentration (Fig. 3 B), and glomerular IgG deposits
(not shown) whether rats were thymectomized and treated
with the anti-CD8 mAb or not. These results show that
neither CD81 cells nor recent thymic emigrants were in-
volved in the protection.
Protection of Mercury-induced Autoimmunity by LEWHg
CD41 T Cell Lines Is TGF-b–dependent. We next exam-
ined whether the inhibition of mercury disease induced by
transfer of LEWHg T cell lines depends on the production
of TGF-b in vivo. Interestingly, blocking TGF-b by ad-
ministration of 1D11-16 mAb at the time of mercury dis-
ease induction completely abrogated the LEWHgA-medi-
ated protective effect (Fig. 4). This is exemplified by the
restoration of autoantibody production (Fig. 4 A), IgE syn-
thesis (Fig. 4 B), and the reappearance of kidney Ig deposits
to levels comparable to those observed in HgCl2-injected
control rats (not shown). Administration of a different
TGF-b–specific mAb (2G.7) also prevented the protection
induced by the transfer of LEWHgA T cells (Table 2).
Treatment with anti-TGF-b mAb alone did not influence
HgCl2-induced autoimmune syndrome.
To demonstrate that TGF-b–dependent inhibition of
Th2-mediated autoimmunity is not a unique property of
LEWHgA T cell line, we tested the effect of anti-TGF-b
mAb administration on the protection induced by the
LEWHgA and two other self–MHC class II reactive T cell
lines. LEWHgA, LEWHgB, and LEWHgC T cell lines have
a comparable regulatory potential when transferred to F1
rats before induction of HgCl2-induced disease (Table 2).
Administration of the anti-TGF-b 2G.7 mAb at the time
of disease induction completely reverted the protective ef-
fect induced by the transfer of LEWHg T cell lines as
shown by the complete restoration of the disease criteria
including loss of body weight (Table 2).
Taken together our data show that three autoreactive
anti-self–MHC class II T cell lines independently derived
from HgCl2-injected LEW rats prevent Th2-mediated au-
toimmune disorders in (LEW 3 BN)F1 rats, and that their
strong immunoregulatory potential is dependent on the
production of TGF-b.
Discussion
This study shows that five autoreactive anti-self–MHC
class II T cell lines derived from distinct HgCl2-injected
LEW rats protect susceptible (LEW 3 BN)F1 rats from
HgCl2-induced, Th2-mediated autoimmunity. These lines
produce TGF-b that is responsible for the protection ob-
served.
An increase in serum IgE concentration, although con-
siderably less than in controls, persisted in HgCl2-injected
Figure 2. Incidence of F1 rats with glomerular IgG deposits (number
in brackets) and immunofluorescence score in HgCl2-injected rats, con-
trol rats, and rats injected with HgCl2 and, 2 wk before, with one of the T
cell lines. The immunofluorescence score concerns only rats that exhib-
ited glomerular IgG deposits.
Figure 3. Effect of thymectomy and CD81 cell depletion on the pro-
tective effect of the LEWHgA T cell line on HgCl2-induced disease. An-
tilaminin antibody titer (A) and serum IgE concentration (B) in HgCl2-
injected rats (h, n 5 5), HgCl2-injected rats that received the LEWHgA
T cell line two weeks before (j, n 5 9), thymectomized rats injected
with HgCl2 and anti-CD8 mAb ( , n 5 4), and thymectomized rats in-
jected with the LEWHgA T cell line 2 wk before HgCl2 and anti-CD8
mAb administration (r, n 5 4).
Figure 4. Ability of the anti-TGF-b (1D11.16) mAb to reverse LEWHgA-
mediated protection from mercury disease. Antilaminin antibody titer (A)
and serum IgE concentration (B) in HgCl2-injected rats (h, n 5 5), and
HgCl2-injected rats 2 wk after adoptive transfer of the LEWHgA T cell
line treated (m, n 5 4) or not (j, n 5 4) with the 1D11.16 anti-TGF-b
mAb (2 mg at day 22, 0, 3, 6, and 9 with respect to the first HgCl2 injec-
tion). The result is a pool of two independent experiments.1773 Bridoux et al.
rats transferred with the LEWHg T cell lines. This was pos-
sibly due to the recently described direct effect of HgCl2 on
IL-4 gene transcription (20).
Autoreactive anti–MHC class II T cells that may enhance
or suppress immune responses have been described in nor-
mal situations and are responsible for the autologous mixed
lymphocyte reaction (see review in reference 21). Similar
cells may also participate in the peripheral control of patho-
genic autoreactive T cells. Thus, autoreactive anti–MHC
class II T cell lines derived either from diabetic biobreeding
rats, or from nondiabetic NOD mice prevent autoimmune
diabetes when transferred to diabetes-prone biobreeding rats
(22) or NOD mice (23), respectively. HgCl2 has been re-
cently shown to induce a polyclonal activation of T cells in
both BN and LEW rats (24), and thus, probably allows,
among other T cells, the expansion of autoreactive anti-
self–MHC class II T cells, from precursors present in nor-
mal animals (25).
The mechanism of action of these autoreactive, regula-
tory T cells is not yet completely understood. We will first
discuss the role of cytokines and then the nature of cells in-
volved in protection. Our results show that protection is
provided by TGF-b. We cannot rule out that other cyto-
kines produced by these lines also play a role in the regula-
tion observed, but neutralization of TGF-b alone abro-
gated the regulatory effect of the line indicating that this
cytokine was of major importance. The regulatory T cell
lines described in other systems (26) were not tested for
their ability to produce TGF-b, except for those derived
from animals orally tolerized with myelin basic protein that
were able to prevent EAE in a TGF-b–dependent manner
(27–29). However, there is now large evidence that TGF-b
plays a major role in controlling the emergence of several
autoimmune or inflammatory diseases (30–39).
A second point to be discussed concerns the nature of
the cells involved in the protection. One possibility is that
the T cell lines are responsible by themselves for the effect
through TGF-b production. Powrie and co-workers have
shown that autoaggressive and regulatory T cells coexist in
normal rats and mice (40, 41). The autoaggressive Th1-like
subset induces severe immunopathological manifestations,
such as colitis in mice, when transferred into immunocom-
promised recipients. The regulatory Th2-like subset, by con-
trast, has no pathogenic effect and, in addition, prevents
manifestations induced by the former subset. Powrie et al.
have shown in mice that this protection was due to TGF-b,
and not to IL-4 (42). The LEWHg T cell lines might be-
long to this regulatory subset, but interestingly, do not have
a Th2-like phenotype since they produce IL-2 and IFN-g
but no detectable IL-4 with a biological assay except for
one T cell line. Taken together, these results identify self-
reactive T cells producing, in addition to TGF-b, either
Th1- or Th2-associated cytokines, with a strong regulatory
potential in both Th1- and Th2-mediated autoimmune
diseases. Another nonexclusive possibility is that the T cell
line recruits other T cells that participate in protection. In
this respect, CD81 T cells are crucial in the protective effect
of the LEWHgA CD41 T cell line towards EAE in LEW
rats (8). CD81 cells play no role in the protection of F1 rats
from HgCl2-induced autoimmunity since protection was
still observed in rats profoundly depleted of CD81 cells af-
ter thymectomy and anti-CD8 mAb treatment. The differ-
ence in CD81 cell requirement in both situations could be
due to the different genetic make up of the recipients or to
differences in experimental models. That the LEWHgA T
cell line had to be injected 2 wk before the first HgCl2 in-
jection is compatible with a recruitment of CD41 cells by
the T cell line. If recruited cells play a role in protection
Table 2. Effect of the Anti-TGF-b mAb (2G.7) on the Protection Mediated by the LEWHg T Cell Lines on HgCl2-mediated
Autoimmunity in F 1 Rats
T cell line No. of rats
Anti-TGF-b
mAb (2G.7) Serum IgE conc.*
Antilaminin
antibody titer*
Glomerular-
bound IgG‡
Loss of body
weight
mg/ml AU/ml % initial weight
2 5 2 2,010 6 640 24 6 9 3.4 6 0.4 22 6 5
2 3 1 3; 315 6 550 33 6 5 2.7 6 0.6 25 6 3
LEWHgA 5 2 370 6 150 9 6 6 0.6 6 0.9 8 6 5
LEWHgA 2 1 3,800; 2,850 31; 66 4; 3 25; 24
LEWHgB 3 2 270 6 300 4 6 6 0.4 6 0.6 5 6 1
LEWHgB 2 1 5,040; 4,860 40; 37 4; 1 26; 27
LEWHgC 3 2 315 6 260 2 6 4 0.7 6 0.6 5 6 3
LEWHgC 2 1 5,040; 4,990 29; 37 3; 3 23; 21
Results are expressed as mean 6 SD when the number of rats was $3; otherwise individual values are given.
*Values for serum IgE concentration and antilaminin antibody titer represent values at the peak of the disease (day 14 or 21 after the first injection of
HgCl2).
‡Kidneys were processed at time of killing for immunofluorescence studies and scored on a scale from 0 to 4.1774 Self–MHC Class II–reactive T Cells Abolish Th2-mediated Autoimmunity
against HgCl2-induced autoimmunity, they could resemble
three previously described regulatory T cell populations. (a)
The first possiblity is recent thymic emigrants, CD41, or
CD81 T cells that have been converted into regulatory cells
by the autoreactive T cells selected on thymic epithelium in
an IL-4–independent manner (43). It is unlikely that re-
cruited recent thymic emigrant cells were at play in our
model since thymectomized rats injected 3 wk later with
the LEWHgA T cell line and injected with HgCl2 were
still protected. (b) The recruited T cells could be similar
to the antiidiotypic or antiergotypic T cells described by
Lohse et al. (44). (c) They could also be related to regula-
tory cells guided to tolerance in the so-called infectious tol-
erance model (45). These hypotheses are currently being
tested.
To conclude, the fact that HgCl2 can induce the expan-
sion, among other T cells, of a subset of regulatory T cells
that may recognize ubiquitous peptides in the context of
MHC class II molecules is probably of importance for our
understanding of the regulatory circuits involved in au-
toimmunity. Depending upon the strain tested, those T cells
could produce different cytokines: self MHC class II–reac-
tive T cells developing in BN rats produce IL-4 and induce
Th2-mediated disorders, whereas T cells expanding in LEW
rats preferentially produce TGF-b responsible for down-
regulation of autoimmunity.
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